Based composition and its use Arthrospira 机翻标题: 暂无翻译,请尝试点击翻译按钮。

源语言标题
(JP5117193) アルスロスピラ​を​ベース​と​する​組成​物​及び​その​利用
公开号/公开日
JP2008518977 A 2008-06-05 [JP2008518977]JP5117193 B2 2013-01-09 [JP5117193] / 2008-06-052013-01-09
申请号/申请日
2007JP-0539420 / 2005-11-03
发明人
Duncan Kelvin Winston;Johnston Peter Owen;Brown Ashley Michael;
申请人
VAI PORT BIO AUSTRALIA;
主分类号
IPC分类号
A01N-043/50A01N-043/653A01N-063/00A01P-003/00A61K-036/02A61P-017/00A61P-017/02A61P-017/04A61P-017/06A61P-017/10A61P-031/04
摘要
(JP5117193) The present invention concerns a composition comprising physiologically stressed Arthrospira maxima for use as a biocide and/or therapeutic.  The invention also concerns a method for preventing or treating an infection or infestation of a subject by an organism, wherein the method comprises the step of administering to the subject an effective amount of a composition comprising physiologically stressed Arthrospira.  (From EP2502983 A1)
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2004AU-0906317 2004-11-03 2005WO-AU01693 2005-11-03
主权利要求
(JP5117193) 1. For topical use is in a subject in the manufacture of the composition Arthrospira-based method, (1) nutritional deficiency or light, dehydration, or about 80% Arthrospira is growth by removing liquids,Arthrospira physiologically stressed electIvely cellulosequick step; and an effective amount of a biocidal action, (2) with respect to the stressed Arthrospira and above (1), to a subject in a carrier suitable for topical administration, in a solvent, base or excipient comprising the step of mixing, wherein the effective amount of a biocidal effects, fungi, bacteria or virus that is the effective amount for stop, wherein the Arthrospira is not freeze-driedmethod.  2. Produced by a method according to claim 1 Arthrospira-based composition.  3. In a subject Eseliericia, bacteria or virus are used as topical Arthrospira-based composition produced by the method of 80%, (1) Arthrospira ACPPE liquid that can be grown in, the step of providing a physiologically stressed Arthrospira stressed Arthrospira and ; (2), adapted to remove contaminants in the washing step and drying the washed Arthrospira of ; (3) is, not lyophilizedstep; after cleaning and (4), and an effective amount of a biocidal action against Arthrospira, carrier suitable for topical administration, solvent, excipient or a mixture of FAPG no addresscomprising quick step.  4. Claim 3 Arthrospira produced by the method of topical use made from the composition.  5. For use as a topical antimicrobial composition comprising, in response to a physiological stress, dried,Arthrospira and an effective amount of the bactericide, suitable for topical administration to a subject in with a carrier, solvent, base or excipient includes, physiological stress, nutrient deficiency or light, dehydration, or about 80% liquids from growing Arthrospira ACPPE achieved by, beforeserial Arthrospira is not freeze-dried composition.  6. The subject, a human, an animal, an agricultural or horticultural product, soil or artificial claim 5 composition selected from the structure.  7. To the subject a topical fungal infection or prevent or treat RNAinto in manufacture of a medicament, for an effective amount of a bactericidal, dried,and physiologically stressed Arthrospira, suitable for topical administration to a subject of the carrier, solvent, base or excipient for the treatment of, physiological stress, nutrient deficiency or light, dewatehng, or a liquid that can be about 80% Arthrospira ACPPE growth achieved by, beforeserial Arthrospira is used which does not freeze-dried.  8. In the manufacture of a topical germicidal composition method , (1) nutritional deficiency or light, dehydration, or about 80% microbial growth Arthrospira by removing liquidsArthrospira in the step of providing a physiological stress; and (2) physiologicalupon receiving a stress, dried, Eseliericia actioneffective amount The (1) and Arthrospira of, suitable for topical administration to the subject a carrier, a solvent, which is a mixture of excipients FAPG comprising, wherein the Arthrospira is not lyophilizedmethod.  9. In response to a physiological stress, dried,Arthrospira and an effective amount of a bactericidal, bacteriostatic agent 1 and at least one synergistic combination, suitable for topical administration to the subject a carrier, solvent, base or excipient includes, physiological stress, nutrient deficiency or light, dehydration, or about 80% liquids Arthrospira ACPPE growth is achieved by, whereinArthrospira is not lyophilized topical antiseptic composition.  10. The bacteriostatic agent, terbinafine, bifonazole, clotrimazole, miconazole, econazole, ketoconazole and tolnaftate claim 9 is selected from the group consisting of topical antiseptic composition.  11. To the subject a topical fungus infection or to prevent or treat RNAinto in manufacture of a medicament, for an effective amount of a bactericidal, dried,physiologically stressed Arthrospira and, at least one of 1 and a bacteriostatic agent, topical administration to the subject in a suitable carrier, solvent, base or excipient for the treatment of, physiological stress, nutrient deficiency or light, dewatehng, or a liquid that can Arthrospira about 80% growth is accomplished by ACPPE,Arthrospira wherein is used not freeze-dried.  12. The bacteriostatic agent is, terbinafine, bifonazole, clotrimazole, miconazole, econazole, ketoconazole and tolnaftate is selected from the group consisting of claim 11.  13. Sterilizing the composition locally method , (1) nutritional deficiency or light, dehydration, or about 80% Arthrospira is growth by removing liquidsphysiological step of applying a stress to the Arthrospira; and (2) dried,upon receiving a stress, an effective amount of the microbicidal The (1) and Arthrospira of, at least one of 1 and a bacteriostatic agent, suitable for topical administration to the subject a carrier, a solvent, base or excipient mixture, and freeze drying the Arthrospira is not step.  14. A dried,in response to a physiological stress, and an effective amount of a bactericidal Arthrospira, applied topically to a subject in a suitable carrier, solvent, base or excipient includes, physiological stress, nutrient deficiency or light, dehydration, or about 80% liquids Arthrospira ACPPE growth is achieved by, whereinArthrospira is not lyophilized topical bactericidal composition.  15. Claim 14 in the subject is a human the composition of the above.  16. To a subject a topical bacterial infection or entry for the manufacture of a medicament for the prevention or treatment, an effective amount of a bactericidal against, dried,and physiologically stressed Arthrospira, suitable for topical administration to the subject a carrier, solvent, base or excipient for the treatment of, physiological stress, nutrient deficiency or light, dewatehng, or a liquid that can Arthrospira about 80% growth is accomplished by ACPPE, whereinArthrospira is used not freeze-dried.  17. The bacterial infection is, use of claim 16 caused by Propionibacterium acne.  18. In the manufacture of a topical germicidal composition method , (1) nutritional deficiency or light, dehydration, or about 80% liquids from growing Arthrospira by removingphysiologically stressing Arthrospira step; and (2) upon receiving a stress, dried,Arthrospira and bactericidal effective amount of the above (1), which is suitable for topical administration to a subject of the carrier, solvent, base or excipient or a mixture of, physiological stress, nutrient deficiency or light, dehydration, or a liquid that can grow is from about 80% Arthrospira ACPPE achieved by, saidArthrospira is not lyophilized step.  19. To mammalian skin for topical use in the treatment or prevention of abnormalities in the composition, of the above compositions is, dried,in response to a physiological stress, and an effective amount of a biocidal action Arthrospira, applied topically to the mammal in a suitable carrier, solvent, base or excipient includes, physiological stress, nutrient deficiency or light, dewatehng, or 80% of the liquid Arthrospira ACPPE growth can be accomplished by,effective amount with respect to said biocidal action, fungi, bacteria or virus to an effective amount, the Arthrospira is not freeze-dried composition.  20. To a mammal for the treatment or prevention of abnormalities in the skin in the manufacture of a medicament, an effective amount of a biocidal action, dried,physiologically stressed Arthrospira and, in a carrier suitable for topical administration to the mammal, solvent, base or excipient for the treatment of, physiological stress, nutrient deficiency or light, dehydration, or 80% and growing the Arthrospira ACPPE liquid which may be achieved by about,  according to the effective amount of a biocidal action, fungi, bacteria or viruses in an amount effective to, in the above-mentioned lyophilized Arthrospira is not used.  21. The above-mentioned abnormalities in the skin, pitted, acne damage, rosacea, red portions with, crack, a burn, a water blister, psoriasis, eczema, desquamates Trombiculiasis, wrinkles, a papule, stomatitis, damage, pustules, trauma, neonatal HRTF dermatitis, diaper rash, ulcerations, cold sores, razor surrenders, chickenpox, dermatitis, selected from the group consisting of cracked heels and elbows of claim 20 are used.  22. A dried, physiologically stressed Arthrospira and bactericidal effective amount, to the subject a carrier suitable for local application, solvent, base or excipient includes, physiological stress, nutrient deficiency or light, dehydration, or about 80% liquids Arthrospira ACPPE growth is achieved by, beforeserial Arthrospira is not lyophilized topical antiviral composition.  23. A dried, physiologically stressed Arthrospira and, applied to a subject in a carrier suitable for local, solvent, base or excipient, for the prevention or treatment of a viral infection in a subject locally in the manufacture of a medicament for use, physiological stress, nutrient deficiency or light, dehydration, or about 80% liquids from growing Arthrospira ACPPE achieved by,wherein Arthrospira is used which does not freeze-dried.  24. The manufacturing method of the anti-viral composition comprising , (1) nutritional deficiency or light, dehydration, or a liquid that can grow is from about 80% Arthrospira by removingphysiologically stressed Arthrospira in, (2) an effective amount, to form a dried, The (1) stressed Arthrospira and of, suitable for topical administration to the subject a carrier, solvent, base or excipient comprising the steps of mixing, wherein the Arthrospira is not freeze-dried method.  25. Claim 1 A. maxima is in the Arthrospira.
法律状态
(JP5117193) LEGAL DETAILS FOR JP2008518977  Actual or expected expiration date=2025-11-03    Legal state=ALIVE    Status=GRANTED     Event publication date=2005-11-03  Event code=JP/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=JP JP2007539420  Application date=2005-11-03  Standardized application number=2007JP-0539420     Event publication date=2008-06-05  Event code=JP/A  Event indicator=Pos  Event type=Examination events  Published application  Publication country=JP  Publication number=JP2008518977  Publication stage Code=A  Publication date=2008-06-05  Standardized publication number=JP2008518977     Event publication date=2008-09-09  Event code=JP/A621  Event indicator=Pos  Event type=Examination events  Written request for application examination  Effective date of the event=2008-09-08  JAPANESE INTERMEDIATE CODE: A621     Event publication date=2008-09-09  Event code=JP/A521  Event type=Restitution or restoration  Written amendment  Effective date of the event=2008-09-08  JAPANESE INTERMEDIATE CODE: A523     Event publication date=2011-09-23  Event code=JP/A521  Event type=Restitution or restoration  Written amendment  Effective date of the event=2011-09-22  JAPANESE INTERMEDIATE CODE: A523     Event publication date=2011-11-02  Event code=JP/A131  Event indicator=Neg  Event type=Examination events  Notification of reasons for refusal  Effective date of the event=2011-11-01  JAPANESE INTERMEDIATE CODE: A131     Event publication date=2012-02-01  Event code=JP/A601  Event type=Examination events  Written request for extension of term  Effective date of the event=2012-01-31  JAPANESE INTERMEDIATE CODE: A601     Event publication date=2012-02-08  Event code=JP/A602  Event type=Examination events  Written permission of extension of term  Effective date of the event=2012-02-07  JAPANESE INTERMEDIATE CODE: A602     Event publication date=2012-02-29  Event code=JP/A521  Event type=Restitution or restoration  Written amendment  Effective date of the event=2012-02-28  JAPANESE INTERMEDIATE CODE: A523     Event publication date=2012-03-22  Event code=JP/A02  Event indicator=Neg  Event type=Event indicating Not In Force  Decision of refusal  Effective date of the event=2012-03-21  JAPANESE INTERMEDIATE CODE: A02     Event publication date=2012-07-21  Event code=JP/A521  Event type=Restitution or restoration  Written amendment  Effective date of the event=2012-07-20  JAPANESE INTERMEDIATE CODE: A523     Event publication date=2012-08-18  Event code=JP/A521  Event type=Restitution or restoration  Written amendment  Effective date of the event=2012-08-01  JAPANESE INTERMEDIATE CODE: A523     Event publication date=2012-08-29  Event code=JP/A521  Event type=Restitution or restoration  Written amendment  Effective date of the event=2012-08-28  JAPANESE INTERMEDIATE CODE: A523     Event publication date=2012-09-03  Event code=JP/A911  Event type=Examination events  Transfer of reconsideration by examiner before appeal (zenchi)  Effective date of the event=2012-08-31  JAPANESE INTERMEDIATE CODE: A911     Event publication date=2012-09-14  Event code=JP/TRDD  Event indicator=Pos  Event type=Administrative notifications  Trial decision date    Event publication date=2012-09-26  Event code=JP/A01  Event indicator=Pos  Event type=Event indicating In Force  Written decision to grant a patent or to grant a registration (utility model)  Effective date of the event=2012-09-25  JAPANESE INTERMEDIATE CODE: A01     Event publication date=2012-09-27  Event code=JP/A01  Event indicator=Pos  Event type=Event indicating In Force  Written decision to grant a patent or to grant a registration (utility model) JAPANESE INTERMEDIATE CODE: A01     Event publication date=2012-10-25  Event code=JP/A61  Event indicator=Pos  Event type=Event indicating In Force  First payment of annual fees (during grant procedure)  Effective date of the event=2012-10-17  JAPANESE INTERMEDIATE CODE: A61     Event publication date=2012-10-26  Event code=JP/R150  Event indicator=Pos  Event type=Event indicating In Force   Certificate of patent (=grant) or registration of utility model JAPANESE INTERMEDIATE CODE: R150     Event publication date=2012-10-29  Event code=JP/FPAY  Event indicator=Pos  Event type=Event indicating In Force  Event type=Payment or non-payment notifications  Renewal fee payment   Annual fees payment date=2012-10-29     Year of payment of annual fees=3  PAYMENT UNTIL: 20151026     Event publication date=2013-01-09  Event code=JP/B2  Event indicator=Pos  Event type=Event indicating In Force  Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)  Publication country=JP  Publication number=JP5117193  Publication stage Code=B2  Publication date=2013-01-09  Standardized publication number=JP5117193     Event publication date=2015-10-13  Event code=JP/R250  Event indicator=Pos  Event type=Payment or non-payment notifications  Receipt of annual fees JAPANESE INTERMEDIATE CODE: R250     Event publication date=2016-10-18  Event code=JP/R250  Event indicator=Pos  Event type=Payment or non-payment notifications  Receipt of annual fees JAPANESE INTERMEDIATE CODE: R250
专利类型码
AB2
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部